Synairgen plc Posting of Annual Report and Notice of AGM (3419O)
17 May 2018 - 4:01PM
UK Regulatory
TIDMSNG
RNS Number : 3419O
Synairgen plc
17 May 2018
Press release
Synairgen plc
('Synairgen' or the 'Company')
Posting of Annual Report and Notice of AGM
Southampton, UK - 17 May 2018: Synairgen (LSE: SNG), the
respiratory drug discovery and development company, announces that
on 17 May 2018 it posted its full Audited Report and Accounts for
the twelve months ended 31 December 2017 (the "Annual Report") to
its shareholders together with the Notice of Annual General Meeting
("AGM"). The Annual Report and Notice of AGM are also available on
the Company's website www.synairgen.com.
The AGM will be held at the offices of Fladgate LLP, 16 Great
Queen Street, London WC2B 5DG on 22 June 2018 at 11 am.
- Ends -
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Max Bullen-Smith (Corporate Finance)
Stephen Norcross (Corporate Broking)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and
Investor
Relations)
Mary-Jane Elliott / Sukaina Virji / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on asthma and COPD, uses its differentiating human
biology BioBank platform and world-renowned international academic
KOL network to discover and develop novel therapies for respiratory
disease. Leveraging its scientific and clinical facilities at
Southampton General Hospital, the Company uses in vitro and ex vivo
models to progress opportunities into clinical development. The
BioBank of human samples is used in these models to increase
confidence in the likelihood of successful drug development. Core
to Synairgen's business strategy is the realisation of value via
licensing transactions. In August 2015 the Company entered into a
collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to
reduce fibrosis in patients with idiopathic pulmonary fibrosis
(IPF). In December 2017 the collaboration agreement was amended as
Pharmaxis took on full responsibility for the programme, with
Synairgen receiving a GBP5 million upfront payment and circa 17% of
any future partnering proceeds from all fibrotic indications.
Synairgen is quoted on AIM (LSE: SNG). For more information about
Synairgen, please see www.synairgen.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOABLGDUGXBBGIL
(END) Dow Jones Newswires
May 17, 2018 02:01 ET (06:01 GMT)
Synairgen (LSE:SNG)
Historical Stock Chart
From Apr 2024 to May 2024
Synairgen (LSE:SNG)
Historical Stock Chart
From May 2023 to May 2024
